Columbus, Ohio – A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC – James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.
The findings, reported in the journal Science Advances, also suggest that the protein might be useful for predicting which cancer patients are less likely to respond to the form of therapy called immune checkpoint blockade.
The protein is called PCBP1, or poly(C)-binding protein 1. The researchers found that PCBP1 helps shape immune responses by ensuring that adequate numbers of activated immune T cells differentiate into cytotoxic T cells, which kill cancer cells. At the same time, PCBP1 prevents the development of too many regulatory T cells, which do not kill cancer cells.
“Our findings suggest that PCBP1 is a global intracellular immune checkpoint, and that targeting it would offer a way to influence antitumor responses during immune therapy,” says principal investigator Zihai Li, MD, PhD, a professor in the Division of Medical Oncology at Ohio State and director of the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSUCCC – James. Li is also a member of the OSUCCC – James Translational Therapeutics Research Program.
“Immune checkpoint blockade therapy has revolutionized cancer treatment, especially in melanoma, non-small cell lung, and head and neck cancer,” says first author Ephraim Abrokwa Ansa-Addo, PhD, an assistant professor in the Division of Medical Oncology and also a member of the Translational Therapeutics Research Program. “But we need better ways to identify which patients will benefit from the therapy. PCBP1 may help us do that.”
PCBP1 belongs to a family of molecules called RNA binding protein. It controls gene expression when immune T cells differentiate into either regulatory T cells or into cytotoxic T cells, which carry out immune responses against infection and cancer. (Cytotoxic T cells are a type of effector T cell.)
In activated T cells, PCBP1 prevents cytotoxic T cells from converting to regulatory T cells, thereby promoting immune responses against tumors.
For this study, researchers used cell lines, tumor models, animal models, and models of diabetes and graft-vs-host disease to achieve a better understanding of the role of PCBP1 in T cells. Graft-vs-host disease is a condition in which a donor’s T-cells (graft) view the patient’s health cells (host) as a foreign and then attack and damage those normal cells.
Key findings include:
- In a non-cancer setting, higher PCBP1 activity promotes cytotoxic T-cell functions that inhibit tumor development and progression.
- In a cancer setting such as the tumor microenvironment, higher PCBP1 activity prevents cytotoxic T cells from expressing factors such as PD-1, TIGIT and VISTA, which produce conditions less favorable to immune checkpoint blockade therapy.
- In a cancer setting, lower PCBP1 in cytotoxic T cells triggers expression of PD-1 and other factors that suppress the T cells’ cancer immune responses, producing conditions more favorable to immune checkpoint blockade therapy.
“Overall, our data indicate that PCBP1 shapes tolerance and immunity by distinctively regulating cytotoxic T-cell versus regulatory T-cell differentiation, and that it could be a marker for response to immune checkpoint blockade therapy,” Li says.
This research was supported by the National Institutes of Health (CA188419, AI070603, and CA186866) and the American Cancer Society.
Other researchers involved in this study were Brian Riesenberg, The Ohio State University; Supinya Iamsawat, Davis Borucki, Michelle H. Nelson, Dongjun Chung, Chrystal M. Paulos, Bei Liu, Xue-Zhong Yu, Jin Hyun Nam and Philip H. Howe, Medical University of South Carolina; Huai-Cheng Huang, National Taiwan University; and Caroline Philpott, National Institute of Diabetes and Digestive and Kidney Disease.
About the OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.